3803 - Clinical Outcomes Following Definitive Chemoradiation In Patients with Glassy-Cell Cervical Carcinoma: A Single Institution Retrospective Analysis
Presenter(s)
S. Shrestha, D. Sanaka, J. A. Asper, C. Kluwe, G. D. Lewis, and A. Le; Department of Radiation Oncology, Mays Cancer Center, UT Health San Antonio, San Antonio, TX
Purpose/Objective(s):
Glassy Cell Cervical Carcinoma (GCCC) is an aggressive and rare subtype of adenosquamous cell carcinoma (ASC) with worse clinical outcomes in both early-stage and locally advanced diseases compared to other histologies. The purpose of this retrospective study is to report clinical outcomes including the progression free survival (PFS) and overall survival (OS) for patients with GCCC treated with definitive chemoradiation.
Materials/Methods:
A retrospective data from a single institution was collected for patients diagnosed with GCCC and completed definitive chemoradiation from 2014 to 2025. Demographic, clinical and treatment related data were retrospectively collected for patients, including age at diagnosis, race, insurance status, cancer staging (The International Federation of Gynecology and Obstetrics (FIGO)) 2018, course of treatment(s), disease recurrence, date of recurrence, and date of death. We reported PFS (defined as development of one/more new lesions or >20% growth lesion size or date of death) and OS (defined as the time to the last follow-up or death) at 1- and 3- yr using Kaplan Meier survival analyses.
Results:
A total of 17 GCCC patients were treated with definitive chemoradiation between 2014 to 2025. Median age was 36 (range: 25-59 years), with 82% diagnosed before age 50. The cohort included non-Hispanic White (n = 1), Black (n = 1), and Hispanic (n = 15). Insurance status included Medicaid (n= 10), private (n =1), and Carelink, a financial assistance program for uninsured county residents (n=6). The average size of the primary tumor was 6.2 cm (range: 3.8 - 10 cm). Based on the 2018 FIGO staging system, the distribution of patients at presentation was as follows: Stage IIIC (n = 12), Stage IIIB (n = 1), Stage IIA (n = 2), and Stage IB (n = 2). All patients received brachytherapy boost post completion of pelvic external beam radiation therapy (EBRT). A total of 3 patients received adjuvant pembrolizumab post completion of definitive chemoradiation. The 1-yr and 3-yr PFS were 88% and 70% respectively; median PFS not reached. The 1-yr and 3-yr OS were 100% and 85% respectively; median OS not reached.
Conclusion:
Glassy Cell Cervical Carcinoma (GCCC) tends to present at a younger age and has been associated with poorer clinical outcomes compared to other cervical cancer histologies. In our single-institution retrospective review, despite the majority of patients presenting with locally advanced disease, treatment with definitive chemoradiation resulted in encouraging clinical outcomes suggesting that aggressive local therapy may offer meaningful disease control in this rare histologic subtype, though further studies are warranted to validate these outcomes.